Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection

Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection-Single Center Phase II Single Arm Clinical Trial

The purpose of this study is to evaluate the efficiency and toxicity of adjuvant hypofractionation radiotherapy for thymic epithelial tumours after complete resection.

Adjuvant Radiotherapy(Postoperative radiotherapy) is proposed in stage II and III thymic carcinoma，stage III thymoma，stage IIB B2/B3 thymomas.

Hypofractionation Radiotherapy is used in this study. The purpose of this study is to evaluate the efficiency and toxicity of adjuvant hypofractionation radiotherapy for thymic epithelial tumours after complete resection.

Inclusion Criteria:

• Thymoma and Thymic carcinoma confirmed by histology or cytology
• R0 resection (complete resection)
• stage II and III thymic carcinoma，stage III thymoma，stage IIB B2/B3 thymomas.
• Karnofsky performance status(KPS) 80, 90 or 100.
• Having sufficient Pulmonary function, renal function and liver function. Neutrophile granulocyte count>1.5×109 /L, platelet count>80×109 /L, hemoglobin ≥10g/dL.

Exclusion Criteria:

• Prior thoracic radiotherapy.
• Uncontrolled Comorbidities.
• Pregnant or nursing mother.
• Pneumonia